遗传学在难治性免疫性血小板减少症中的作用
难治性免疫性血小板减少症(rITP)患者发病率和死亡率增加,但目前对难治原因了解有限且无标志物指导新治疗。本文综述了rITP的遗传学证据,包括遗传性病因及获得性突变(尤其是导致细胞毒性T细胞克隆扩增的突变)。
要点
- rITP患者发病率和死亡率增加,难治原因不明且缺乏指导新治疗的标志物。
- 家族性ITP罕见且双胞胎研究少,提示单纯遗传病因可能性低。
- 遗传突变可为多种自身免疫病提供背景,rITP可能涉及遗传易感或获得性突变。
核心结论
- 理解rITP难治的原因对确定新治疗方案至关重要,其发病机制通常被认为是遗传易感性结合环境触发因素。
研究设计与样本
- 综述,探讨rITP的遗传性病因或获得性突变(尤其是导致细胞毒性T细胞克隆扩增的突变)的证据。
主要发现
- 家族性ITP仍罕见且双胞胎研究少,提示单纯遗传病因可能性低。
- 遗传突变可为多种自身免疫病提供背景。
- 综述探索了rITP的遗传性病因或获得性突变(尤其是导致细胞毒性T细胞克隆扩增的突变)的证据。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with refractory immune thrombocytopenia (rITP) have increased morbidity and mortality. Currently, there is limited understanding of the cause of refractoriness and no markers to help direct novel treatment options. Understanding the reason(s) for refractoriness is crucial to determining novel treatment options. The pathogenesis underlying rITP has generally been thought to be an underlying genetic predisposition with an environmental trigger. Familial ITP remains rare, and there are few twin studies, suggesting that a simple genetic cause is unlikely. However, genetic mutations provide the background for several autoimmune diseases. In this review, we explore the evidence of either an inherited genetic cause of rITP or an acquired mutation, in particular one resulting in clonal expansion of cytotoxic T cells.
引用
- Zehnder JL, Bussel JB, Cooper N, et al. The role of genetics in refractory immune thrombocytopenia. Br J Haematol. 2023. PMID: 37735556. doi:10.1111/bjh.19110
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。